| Journal | Neurogastroenterology and motility |
| Study Type | Cohort |
| Population | Human participants |
This large propensity-matched analysis challenges assumptions about cannabis as therapeutic for cyclical vomiting syndrome, showing increased healthcare utilization among cannabis users. The findings are particularly relevant given the complex relationship between cannabis and gastrointestinal symptoms, including paradoxical hyperemesis syndromes.
This retrospective cohort study analyzed 37,176 adults with CVS using TriNetX data, comparing outcomes between 18,588 propensity-matched pairs with and without cannabis use. Cannabis users were significantly younger (32 vs 39 years) and demonstrated higher rates of all-cause emergency department visits and hospitalizations compared to non-users. The study controlled for demographics, BMI, comorbidities, and CVS treatments through propensity matching. While the association is clear, the observational design cannot establish whether cannabis use worsens CVS outcomes or whether patients with more severe disease are more likely to use cannabis.
“I see this pattern clinically – patients often turn to cannabis for nausea relief, but the relationship with cyclical vomiting is complex and potentially bidirectional. This data reinforces my approach of careful screening for cannabis hyperemesis syndrome in CVS patients using cannabis.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
Table of Contents
- FAQ
- Does cannabis use improve outcomes in patients with Cyclical Vomiting Syndrome?
- Should I recommend cannabis to my CVS patients for symptom management?
- What is the demographic profile of CVS patients who use cannabis?
- Could cannabis use be contributing to or worsening CVS symptoms?
- How should this evidence change emergency department management of CVS patients?
FAQ
Does cannabis use improve outcomes in patients with Cyclical Vomiting Syndrome?
No, this large propensity-matched study of nearly 35,000 individuals found that cannabis use is associated with increased healthcare utilization and poorer outcomes in CVS patients. Cannabis users had significantly more emergency department visits and hospitalizations compared to matched controls who did not use cannabis.
Should I recommend cannabis to my CVS patients for symptom management?
Based on this evidence, cannabis should not be routinely recommended for CVS management as it appears to worsen rather than improve clinical outcomes. The study suggests cannabis use may contribute to increased healthcare burden rather than providing therapeutic benefit for these patients.
What is the demographic profile of CVS patients who use cannabis?
CVS patients who use cannabis tend to be significantly younger than non-users, with a mean age of 31.9 years compared to 39.0 years in non-users. This age difference of approximately 7 years suggests cannabis use patterns may influence CVS presentation timing or diagnosis.
Could cannabis use be contributing to or worsening CVS symptoms?
The study findings suggest this possibility, as cannabis users had worse outcomes despite propensity matching for other variables. This aligns with concerns about cannabis hyperemesis syndrome, which can present similarly to CVS and may complicate diagnosis and treatment.
How should this evidence change emergency department management of CVS patients?
Emergency physicians should screen CVS patients for cannabis use and consider it as a potential contributing factor to frequent ED visits. Cannabis cessation counseling may be an important intervention to reduce healthcare utilization and improve outcomes in these patients.